|
|
|
|
|
|
|
|
|
|
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
Abstract
Background
Paclitaxel
is commonly given as a 3-h infusion every 3 weeks for a variety of
malignancies. Several randomized clinical trials comparing weekly
paclitaxel with Q3-week (Q3W) have produced mixed results in terms of
efficacy and toxicity creating controversy about the ideal dose and
schedule.
Methods
A literature search using PubMed, Cochrane Library, and Proceedings of the American Society of Clinical oncology
from 1995 to 2011 was performed..........Moderators of cancer types, ethnicity, and paclitaxel dose ratio were
analyzed for primary dependent variables.
Results
Ten trials were included....
Conclusion
Weekly paclitaxel has a favorable toxicity profile compared to the current standard of Q3W paclitaxel.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.